



7TH ANNUAL
**ANIMAL HEALTH, NUTRITION
& TECHNOLOGY INNOVATION
EUROPE**

21-23 February • London, UK
@AHInnovation #AHTNI

INNOVATION SHOWCASE FINALISTS 2022

Animal Health, Nutrition and Technology Innovation Europe is the premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.



We are proud to announce the **finalist companies** selected to present at the 2022 Innovation Showcase.

Headline
Partner:



Associate
Partners:



A SPECIAL THANK YOU TO THE SELECTION COMMITTEE

The Selection Committee members were responsible for selecting the showcase companies at **Animal Health, Nutrition and Technology Innovation Europe 2022**. Each of our committee members has an extensive breadth of experience and knowledge across animal health and nutrition industries and will be available for meetings at the conference.



Charles Hoare
Managing Director, Head
of European Healthcare
Stifel



Julia Stephanus
Partner
Borealis Ventures



Claire Smith
Agriculture Biotech VC
Anterra Capital



Cynthia Cole
Partner
Digitalis Ventures



Paul Dick
President
Paul Dick & Associates



Dino Dedic
Senior Managing Director
Guggenheim Partners



Duane Cantrell
Managing Partner
**Fulcrum Global
Capital**



Matthieu Vermersch
VVNP's founder and
Managing Partner
New Protein Capital



Barry Brackner
Seasoned Board Director
& Senior Leader



Laetitia Gerbe
Partner
Seventure Partners



Nicky Deasy
Managing Partner
The Yield Lab Europe



Sebastien Lafon
Founder
Adapt1st



Yoran Meijers
Food Agriculture VC
Anterra Capital



Eli Hasson
Founding Partner
Phil Ventures



Benjamin Shaw
Partner
Borealis Ventures



Sarai Kemp
VP Business Development
Trendlines Agrifood



Matthias Hofer
Managing Partner
Stonehaven Consulting



MAKE THE RIGHT CONNECTIONS

Our meeting mojo platform allows you to preschedule meetings with these exciting start-ups!

Animal Health, Nutrition and Technology Innovation Europe is committed to bringing innovative and inspiring emerging companies together with partners looking to acquire and invest.

To ensure all our attendees make the most valuable connections possible at the Summit, the **MEETING MOJO** platform allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are **most important** in building your business.

MEETING MOJO gives you access to the entire attendee list and allows you to message **AND** invite people to connect during the formal meeting sessions run throughout the day.

SCHEDULED MEETINGS

Who You Will Meet

- + Start-Ups & Early Stage Biotech Companies
- + Business Development Teams from International Pharmaceutical Companies
- + Leadership from Multinational Corporations
- + Mid to late-stage Health and Nutrition Companies
- + Global Distribution Leaders
- + Venture Capital and Private Equity Investors
- + Market Intelligence and Consultancy Providers
- + Universities and National Regulatory Bodies
- + Contract Research & Contract Manufacturing

Join the Finalists:
REGISTER TODAY



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Algenex is a private biotech company with proprietary and patent protected technologies to boost the production of recombinant proteins using Baculovirus vector expression systems (BVES) in insect cells. Their vision is to transform protein production to enable universal access to biotechnology products. Algenex aim to do this by harnessing nature for simple, scalable and cost-efficient manufacturing tools: Chrysalises of the *Trichoplusia ni* (T.ni), the natural host of the baculovirus vector commonly used by the industry, are used in their CrisBio platform as single use natural biocapsules, replacing conventional bioreactors. The result is the ability to produce complex biologicals in a simpler, faster and cheaper way, allowing clients to perform quick proof of concepts with no capex in infrastructure.



Armenta developed a solution that is a striking balance between farmer profitability, farm sustainability and animal welfare by targeting the most pressing disease affecting dairy farming today - bovine mastitis. Annual losses to mastitis could reach >\$5B in the EU and U.S. alone and by utilizing Armenta's technology, a farm can transform these losses to revenue.

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Cody Genetics is using the most sophisticated gene-editing tools to contribute to more sustainable animal production, increase farmers' income, improve animal health and welfare. They believe that gender skewing, disease resistance, and performance enhancement traits are the future of animal breeding.

SEED



Embion Technologies S.A. is a Swiss-based industrial biotechnology and green chemistry company. Thanks to its platform technology, Embion revolutionises biomass processing to make it simpler, more profitable and more sustainable.

They enable the production of highly functional bioactives from biomass for animal nutrition, food & beverages and cosmetics. With this breakthrough technology, they accelerate the development of functional nutrition while significantly reducing cost and time-to-market.

Embion catalyses the future of nutrition toward a circular bioeconomy.

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Healthy Cow first originated in 2014, when their founders, Louis, Richard, and Ed came together over a shared interest in food, dairy, and better animal health and well-being practices for cows. Their backgrounds in biology and veterinary science provided a deep understanding of the interactions of the dairy cows' microbiome from a systems biology approach. One of their first actions was to license the technology relevant to dairy cows' reproductive tract microbiome characterized by Dr Burim Ametaj, Professor of Agriculture at the University of Alberta, Canada.

Now after years of development and field testing, Healthy Cow is launching their first product, ProPreg. ProPreg is a blend of natural prebiotics and probiotics used to augment and maintain a healthy reproductive microbiome during the critical transition period of dairy cattle. ProPreg is safe and easily integrated into farms' existing protocols and routines. ProPreg is the first intra-vaginal probiotic product to assure a healthy and balanced microbiome in the reproductive tract of cattle. ProPreg is specifically formulated with three native bacterial strains that are normally abundant in the reproductive tract of healthy cows. These Lactic Acid Bacteria provide defenses against pathogens and infections.

SEED



Iraka Biotech is a biotechnology committed to One Health and the equitable access of animal vaccines. The company has developed a novel reactor capable of producing vaccines in an environmentally friendly manner through a simple and more user-friendly process. This allows vaccines to produce optimally at a lower cost, without compromising the quality of vaccines.

SEED



MBF Therapeutics is an immunotherapeutics company focused on animal applications of its innovative T-Max immunotherapeutic DNA vaccine platform with significant translational opportunities in human health. Their T-Max platform addresses longstanding shortcomings of traditional viral vaccine technologies.

SERIES C



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Micron Agritech is a highly disruptive start-up with the goal to bring practical technology to the agriculture sector. The company's first product, Micron Kit came from talking to a vet who told us she didn't test her animals for parasites as it takes too long to get results, even though she knew how to do the test, instead dosing them, wasting money on unnecessary medication.

Micron Agritech strive to be at the cutting edge of technology in the agriculture industry, through the implementation of smart systems, utilising machine learning and other cutting-edge technologies. This technological edge is maintained through a constant search for innovative solutions through research and development.

SEED



Soos technology is developing sex determination in poultry embryos for the layer industry. They improve the production capacity of commercial hatcheries by producing more female layers in a safe, non-GMO manner.

Sex reversal in poultry embryos is done using an incubation platform that controls the environmental conditions (temperature, humidity and vibration) during incubation stage, and convert male layers into functional females that can lay eggs. The system is composed of a smart egg-tray and a signal generation system that is monitored and controlled by their Soository system, a data repository and real time monitoring system that runs their proprietary incubation protocol, controls that hatching process, and improves over time using machine learning.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Adivo are committed to providing therapeutic antibodies as a best-in-class treatment option for pets. Their mission is based on their powerful proprietary phage display platform for dogs and for cats.

Initial studies in dogs for two programs, one for chronic inflammatory diseases and one for oncology, have been initiated.

SERIES A



ARK: Acceleration of human drug development programs through parallel animal health-generated clinical insights, leading to innovation flow into animal health with associated regulatory paths to commercial applications.

SERIES A



ControlPoint is developing the first ever single-use, disposable, hand-held test to be used in veterinary clinics to aid in the detection of kennel cough. Test results will be available in about 5 minutes and the test is read using an app on a smartphone or tablet allowing veterinarians to determine the best treatment plan. Dogs can be treated the same day of the visit. Considering the cost of multiple individual tests which require samples to be sent to central laboratories, their device would reduce cost and provide a new source of revenue for veterinarians and replace some laboratory testing for kennel cough.

PRE-SEED



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Doderm has developed a skin care concept for eczema-prone skin. Staphylococci are the predominant bacterial species and increase skin damage and inflammation. Their key active ingredient creates unfavourable conditions for staphylococcal adherence and pathogenic activity.

Doderm's key active ingredient is antibodies from cow's milk. They have the technology and know-how in-house to obtain this antibody in a highly active form and in large quantities. They have developed formulations to optimally apply this active ingredient locally on the skin. Their first product is a hydro repair gel successfully used for dogs and horses.

SEED



Gallant Therapeutics is at the forefront of science, working every day to advance the field of regenerative medicine in animal health, making every (pet) year count. Veterinary regenerative medicine remains far behind the human cell therapy space, despite the field starting more than 15 years ago. Gallant is closing this innovation gap by leveraging their cell therapy platform and fast-tracking the most impactful products in regenerative medicine, including products for canine atopic dermatitis (cAD), feline chronic kidney disease (CKD) (Partnered with a top three animal health company), canine osteoarthritis (OA), feline chronic gingivostomatitis (FCGS) and others.

Gallant has a strong IP portfolio with eight issued patents and 19 applications in process. Partnering with FDA CVM through the Veterinary Innovation Program (VIP) facilitates interaction and timing of their product development strategy. With a core team of industry pioneers, a strong and engaged board of directors, cGMP manufacturing capability, and compelling early clinical data in many indications, Gallant Therapeutics is poised for its first product approval in late 2023 and successive follow-on submissions. Gallant is raising \$30M in a series B round to get two products to approval, progress additional products and get proof-of-concept in their second-generation platform of programmed cells.

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Effective cancer therapy requires delivery of the right drug to the right place at the right time. Nano RED Animal Health is building a next-generation therapy delivery platform that allows a veterinarian to define therapy delivery in real time. Their platform utilises a near-infrared activated liposome, loaded with cytotoxic chemo or immunotherapy; after IV infusion, a veterinarian illuminates the target region with near-infrared light, activating the liposome and releasing the encapsulated cargo. For deep seated tumors, ultrasound can be used to activate liposomes to release the payload. The result is a combination of both direct tumor cell killing by the liposome, as well as precise release of the chemotherapy agent, enabling higher levels of therapy release with lower toxicity.

The versatility of their platform allows us to package a wide variety of agents and to partner with a broad swath of pharmaceutical entities, even as they develop our own in-house pipeline, unlocking value earlier and de-risking long-term development.

Their pipeline includes reformulated, proven chemotherapeutics with improved efficacy and diminished toxicity, as well as novel immunotherapies and encapsulated immunostimulants tuned for precise delivery.

PRE-SEED



JetMeds is developing a platform to optimize the way they dose medications. Turns out, when you remove the human from the job of administering medication, you can improve efficacy while using less drug.

The technology they're building includes wearable connected smart devices that dispense microdoses from cartridges, and software to optimise that dosing.

SEED



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Accurate interpretation of laboratory data requires considerable expertise and experience, especially given the number of diseases and varied species that vets are presented with on a daily basis. General practitioners work under considerable time pressure and there may be little time to consult textbooks or seek specialist help with the interpretation of laboratory findings. Indeed, it is very difficult for general practitioners to stay abreast of the volume of veterinary literature that is published each year.

Pathologica automates the interpretation of routine blood tests, providing rapid, expert-level clinical interpretations at point of care. Targeted recommendations are given to direct clinical investigations. Pathologica helps bridge the knowledge gap, augments clinical reasoning and enhances patient care.



Aging is caused by the dysregulation of multiple systems in the body that manifest itself in age-related disease. Current solutions focus on each problem individually, ignoring the interconnectedness of the challenge. **Rejuvenate Bio** utilises gene therapy, proprietary targets, and the animal health market to bring anti-aging therapies to market in an incredibly capital-efficient manner. With drastically lower regulatory requirements and ever-increasing demand for treatments in animal health, Rejuvenate Bio can drive early revenue and enhance the value of its human programs, both through strong pre-clinical data and long-term validation of its overall approach.

Rejuvenate Bio's lead therapy has demonstrated the ability to treat heart failure, kidney failure, diabetes, and obesity in mice and has also shown to be safe and efficacious in dogs. In 2021, Rejuvenate Bio will complete its final clinical trial in animal health before bringing its first product to market. This trial will also act as the final preclinical study needed for its first human therapy.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Millions of dogs and cats are diagnosed with cancer globally each year. Currently 10% of all veterinary appointments are cancer related. However, there are currently no treatment options available to treat dogs diagnosed with cancer in general practice. Available treatments like chemotherapy and radiation are often expensive, inaccessible and have safety concerns that lead to over 90% of pets not being seen by a veterinary oncologist.

Torigen has brought together the top team of animal health veterinarians, oncologists, researchers and animal health professionals to revolutionise the veterinary cancer industry. They currently offer a personalised cancer vaccine to veterinarians in specialty and general practice and are commercialising new products to the market that are safe, effective and affordable. They will surpass over \$1M in revenue this year and have plans to expand globally, in-license new technologies and grow Torigen into a leading animal health company.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

TECHNOLOGY

The logo for Animoscope, featuring the word "animoscope" in a lowercase, sans-serif font. The "i" and "o" are stylized with a blue and green gradient.

Animoscope is building an all digital veterinary service that provides pet parents with qualified advice and guidance at a fraction of the cost going to the clinic.

They're a data-driven company who built their own triage algorithm, Vetichack (French college of veterinarian approved). Vetichack enables acquisition of extremely qualified user profiles at very low cost, offering Petcare companies a unique data set with hyper-personalised segmentation of user needs.

SERIES A

The logo for Companion, featuring a stylized white dog head icon inside a dark green circle, followed by the word "companion" in a lowercase, sans-serif font.

Companion is on a mission to talk to dogs. They make the world's first autonomous dog training and software platform, coupled with one-on-one coaching and live and on-demand classes, that makes it easy and affordable for everyone to train their dog to professional levels at home.

Using AI and treats, Companion automatically engages your dog with positive reinforcement training for the most important obedience behaviours that help build the human animal bond. This engagement and training has numerous direct benefits such as a more engaged, enriched and relaxed dog. In addition, the platform can perform time intensive behaviour protocols, such as slow-moving noise desensitisation with louder and louder noises paired with counterconditioning or active engagement to help with separation anxiety.

SERIES A

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

TECHNOLOGY



Cynomys are the promoters of conscious, sustainable and animal welfare-oriented livestock farming, with their patented IoT solution for environmental impact monitoring and consumption rate analysis in animal farms: the Cynomys Livestock System.

The Cynomys Livestock System helps farmers to quantify objectively the emissions from their farms and to identify the processes that release more GHG or those affecting animal welfare. They know that if it cannot be measured, it cannot be managed, so they give the livestock sector a way to measure it all.

They are currently present in 9 countries, partnering up with some of the most interesting stakeholders in the field of animal health and nutrition. They want to scale up their presence in the market to become the global benchmark for environmental monitoring in livestock production.

SERIES A



FarmSee utilises computer vision and AI to provide the pig production industry with critical information so far unattainable, such as individual weight and early detection of diseases. Currently, critical KPIs, such as individual pig's continuous weight, are unavailable due to animal welfare concerns, biosecurity and labour intensity. Hence, the pig production ecosystem relies on theoretical and historical data, resulting in significant inefficiencies. FarmSee's solution provides actionable insights driving significant revenue growth and cost optimisation, while ensuring animal welfare.

FarmSee solution is currently used in various markets including Spain, Denmark, USA, Russia, Belarus, and more.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

TECHNOLOGY



Six million dogs and six million cats get cancer every year. Like humans, every animal patient responds differently to an anticancer drug. **ImpriMed** provides an AI-driven personalised drug response prediction service designed for pets with cancer. They use proprietary precision medicine technologies to allow veterinary oncologists to find out the most effective anticancer drugs for individual patients before deciding on a treatment regimen. With 150+ veterinary oncology partners in 32 states of the U.S., ImpriMed has so far provided their precision medicine service to over 2,400 dogs with blood cancers. The veterinary doctors who have used their service say the ImpriMed service extends patients' lifespan, improves patients' quality of life, decreases treatment cost by excluding drugs that are not likely to be effective, and enhances their reputation and revenue.

SERIES A



MI RNA create microRNA biomarker panels to be used as a diagnostic blood test in a variety of species and disease types. This is combined with their AI precision medicine to accurately pinpoint pathology in its early stages. The test is quick, highly sensitive and highly specific and will change the way we look at diagnostics.

Their vision is to create a unique and internationally recognised veterinary diagnostics company. They are revolutionising early disease detection with their pioneering technology, offering a suite of tests, combined with our bespoke AI system. This ground-breaking approach will result in a cascade of ethical, environmental and economic benefits.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

TECHNOLOGY



There are more chickens on the planet than humans, which have the equivalent of a human birthday every 12 hours. With finite labour resources and the current technology available, at best we are able to measure 0.005% of chickens. Poor visibility exposes chicken production to significant financial losses. **Pondus** provides the virtual poultry assistant. Pondus gives those extra informative eyes in the shed 24/7 solving the labour and visibility problem, enabling earlier detection of issues and thus improved efficiency, health, welfare and productivity. What is more, the technology is very efficient - one image is used to provide several important production indicators. With the price point of the technology, farmers will see a 5x return in just 12 months.

SEED



Sylvester.ai creates predictive healthcare products powered by artificial intelligence to improve animal health outcomes across species. They believe animals can live healthier, longer lives when their caregivers can better understand how an animal is feeling.

Tably and Tably Pro-beta, in market since April 2021, use AI-powered technology validated through veterinary pain scales to predict the level of discomfort a cat may be in by simply taking a picture of the cat's face. Tably is a pet owner facing app, while Tably Pro is an app that allows veterinarians to prescribe Tably for remote patient monitoring by taking pictures of the cat during its recovery from a procedure or health event.

SEED



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

TECHNOLOGY



Tibot designs assistance robots for the poultry industry. They believe in Plug & Play robotics, accessible to farmers that improves working conditions, responds to the lack of labour, and generates productivity gains while promoting animal health.

T-MOOV, a Plug & Play robot stimulates birds' movement to prevent floor-eggs, increases mating and fertility, and improves FCR/ADG. Control of the robot, choice of light, sounds and mechanical stimuli is possible through a smartphone App. At the end of the day, the robot goes autonomously to a self-charging base. Their T-NAV robot for broilers is equipped with a high precision indoor geolocalisation system.

SERIES A



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

NUTRITION

AnimalBiome

Digestive and skin conditions account for over 50% of all vet visits in the US and more than 60 million cats and dogs suffer from these conditions annually. The gut microbiome modulates these conditions and holds the key to resolving the root cause of many of these conditions.

AnimalBiome provides personalised health products and services for cats and dogs based on twenty years of microbiome research conducted by their team led by co-founder, and Chief Science Officer, Holly Ganz, PhD. Since 2016, their products have helped thousands of pet parents assess, restore, and maintain the gut health of their cats and dogs through in-home microbiome tests, personalised dietary recommendations, and supplements from the DoggyBiome and KittyBiome brands.

Their company-owned and operated lab and manufacturing facility in Oakland, California houses one of the world's largest microbiome reference databases for cats and dogs which ensures their customers receive highly actionable recommendations for their pets.

SERIES A



Arbion is a biotechnology leader developing highly nutritious, sustainable and innovative protein ingredients for a wide variety of feed applications.

Arbion's protein solution SylPro, is derived from a variety of widely available feedstocks, including wood, that meet the growing needs for high-volume protein sourcing in the aquaculture, pet food and swine industries.

With their innovative manufacturing process and commitment to sustainability, Arbion is poised to meet the protein sourcing challenges of today's food producers while creating solutions that will play a key role in the future of feed.

Arbion is headquartered in Research Triangle Park, North Carolina, with a global location in Paris, France.

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

NUTRITION



Because It's Better is dedicated to providing high-quality, authentic super premium, sustainable, clean, alternative protein pet foods and treats to pet parents nationwide.

They only use environmentally friendly proteins, ingredients, materials and practices. They will practice corporate social responsibility (CSR) initiatives and be transparent to their customer base regarding their business practices and the ingredient they use.

They will commit to educating the global pet community on the advantages of alternative, clean protein and offer them a sustainable option to the pet food they buy today, without sacrificing nutrition, quality or price. In doing so, Because It's Better will meet the rising demand for sustainable pet food and will inspire millions of pet parents to switch to a healthier alternative for their dogs and our planet.

SERIES A



Tonisity is a 5-year-old company that has successfully translated a novel concept of intestinal support physiology to commercial products.

In commercial swine production, the Tonisity products Px and PxW significantly ($P < 0.0001$) reduce early-life pre-weaning mortality and morbidity, although the Tonisity products contain no antibiotics, pre/probiotics, plasma or GMOs. These effects are particularly seen in pigs from birth to 10 weeks of age, which is their most vulnerable period and the biggest opportunity for intervention.

In dogs and cats, Tonisity products (under the DoggyRade/KittyRade banner) provide gut health and hydration benefits, while also giving owners an alternative low-calorie treat experience. Your pet drinks, you both enjoy!

SERIES B



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE

VENUE & PRICING

Etc.venues 133 Houndsditch • London EC3A 7BX

PASS TYPE*	STANDARD PRICING
Showcase Applicant Only available to companies that have applied to present at the Innovation Showcase in 2022	£1,199 + VAT
Emerging Companies & Start Ups, Academics, Charities, Veterinary Practices, Angel and VC Investors For Start-Ups with under £4m in Annual Revenue Please note: Those offering consultancy or market intelligence services do not qualify for this rate	£1,299 + VAT
Delegate Health, Nutrition and Tech companies (under £100m in annual revenue)	£2,499 + VAT
Multinationals CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors and Companies over £100m in annual revenue	£3,199 + VAT

BIG SAVINGS WITH BIG BOOKINGS

SAVE 10% - Book a team of 3+

SAVE 15% - Book a team of 5+

REGISTER
HERE

Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that all prices are plus VAT and a £49 processing fee will apply to any invoices requested. All Prices are in GBP. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com.

